In this executive summary, we describe formulation and manufacturing considerations for development of dry-powder therapeutics for local treatment of lung cancer. A case study is presented in which an approved drug—topotecan—is successfully formulated for DPI administration to the lung.
You may also be interested in:
Latest content
Latest briefing from the Knowledge Center